Royalty Pharma plc Class A Ordinary Shares (RPRX) is a publicly traded Healthcare sector company. As of September 5, 2026, RPRX trades at $60.02 with a market cap of $28.44B and a P/E ratio of 33.91. RPRX moved +0.17% today. Year to date, RPRX is +61.31%; over the trailing twelve months it is +77.32%. Its 52-week range spans $29.66 to $64.38. Analyst consensus is strong buy with an average price target of $65.67. Rallies surfaces RPRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies community data for RPRX shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
| Metric | Value |
|---|---|
| Price | $60.02 |
| Market Cap | $28.44B |
| P/E Ratio | 33.91 |
| EPS | $1.88 |
| Dividend Yield | 0.23% |
| 52-Week High | $64.38 |
| 52-Week Low | $29.66 |
| Volume | 2.92M |
| Avg Volume | 0 |
| Revenue (TTM) | $2.54B |
| Net Income | $1.35B |
| Gross Margin | 0.00% |
7 analysts cover RPRX: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $65.67.